Good day to you. This is Meghana of the Readout, filling in for Ed in this Wednesday edition of Pharmalittle. Here’s what’s happening in PharmaLand:
San Diego’s Neurocrine Biosciences won approval for its drug targeting tardive dyskinesia — a movement disorder seen in patients taking antipsychotic medication. This is the company’s first drug approval. Its stock leapt nearly 25 percent in premarket trading.
About the Author Reprints
